The main drawback of IVTA is the high rate of possible side effects such as glaucoma, cataract formation or endophthalmitis.[9-12]As in CRVO patients, the macular edema is thought to be at least partly triggered by hypoxia-induced expression of vascular endothelial growth factor (VEGF);[13] intravitreally administered antiVEGF antibodies have recently been introduced into the treatment regime for RVO patients.[14]. This evidence concerns the gene VEGFA and endophthalmitis.